Compare Goldman Sachs Group Inc (GS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Novo Nordisk A/S — how do they compare? Goldman Sachs Group Inc trades at $1,113.55 (market cap $339.87B), while Novo Nordisk A/S trades at $51.51 (market cap $222.24B). The key difference: Goldman Sachs Group Inc is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| GS | NVO | |
|---|---|---|
Market Cap | $339.87B | $222.24B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $71.70 |
52-Week Low | $700.41 | $35.29 |
Dividend Yield | 1.56% | 3.56% |
Enterprise Value | — | $241.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
